These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 35570131)
1. Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives. Mollnes TE; Storm BS; Brekke OL; Nilsson PH; Lambris JD Semin Immunol; 2022 Jan; 59():101604. PubMed ID: 35570131 [TBL] [Abstract][Full Text] [Related]
2. Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. Storm BS; Christiansen D; Fure H; Ludviksen JK; Lau C; Lambris JD; Woodruff TM; Brekke OL; Braaten T; Nielsen EW; Mollnes TE J Immunol; 2021 Dec; 207(11):2828-2840. PubMed ID: 34732467 [TBL] [Abstract][Full Text] [Related]
3. A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity. Nilsson PH; Johnson C; Quach QH; Macpherson A; Durrant O; Pischke SE; Fure H; Landsem A; Bergseth G; Schjalm C; Haugaard-Kedström LM; Huber-Lang M; van den Elsen J; Brekke OL; Mollnes TE J Immunol; 2021 Sep; 207(6):1641-1651. PubMed ID: 34380648 [TBL] [Abstract][Full Text] [Related]
4. Venous Air Embolism Activates Complement C3 Without Corresponding C5 Activation and Trigger Thromboinflammation in Pigs. Storm BS; Ludviksen JK; Christiansen D; Fure H; Pettersen K; Landsem A; Nilsen BA; Dybwik K; Braaten T; Nielsen EW; Mollnes TE Front Immunol; 2022; 13():839632. PubMed ID: 35371063 [TBL] [Abstract][Full Text] [Related]
5. Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. Golomingi M; Kohler J; Lamers C; Pouw RB; Ricklin D; Dobó J; Gál P; Pál G; Kiss B; Dopler A; Schmidt CQ; Hardy ET; Lam W; Schroeder V Front Immunol; 2023; 14():1226832. PubMed ID: 37771595 [TBL] [Abstract][Full Text] [Related]
10. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517 [TBL] [Abstract][Full Text] [Related]
11. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Lappegård KT; Christiansen D; Pharo A; Thorgersen EB; Hellerud BC; Lindstad J; Nielsen EW; Bergseth G; Fadnes D; Abrahamsen TG; Høiby EA; Schejbel L; Garred P; Lambris JD; Harboe M; Mollnes TE Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15861-6. PubMed ID: 19717455 [TBL] [Abstract][Full Text] [Related]
12. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models. Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD Front Immunol; 2018; 9():1691. PubMed ID: 30083158 [TBL] [Abstract][Full Text] [Related]
13. Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person. Bergseth G; Lambris JD; Mollnes TE; Lappegård KT Ann Thorac Surg; 2011 Feb; 91(2):527-33. PubMed ID: 21256307 [TBL] [Abstract][Full Text] [Related]
14. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Müller-Calleja N; Ritter S; Hollerbach A; Falter T; Lackner KJ; Ruf W Blood Adv; 2018 May; 2(9):979-986. PubMed ID: 29716893 [TBL] [Abstract][Full Text] [Related]
15. With complements: C3 inhibition in the clinic. Kolev M; Barbour T; Baver S; Francois C; Deschatelets P Immunol Rev; 2023 Jan; 313(1):358-375. PubMed ID: 36161656 [TBL] [Abstract][Full Text] [Related]
16. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Subramaniam S; Jurk K; Hobohm L; Jäckel S; Saffarzadeh M; Schwierczek K; Wenzel P; Langer F; Reinhardt C; Ruf W Blood; 2017 Apr; 129(16):2291-2302. PubMed ID: 28223279 [TBL] [Abstract][Full Text] [Related]
17. Gerogianni A; Bal M; Mohlin C; Woodruff TM; Lambris JD; Mollnes TE; Sjöström DJ; Nilsson PH Front Immunol; 2023; 14():1101387. PubMed ID: 37081885 [TBL] [Abstract][Full Text] [Related]
18. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. Zewde N; Morikis D PLoS One; 2018; 13(6):e0198644. PubMed ID: 29874282 [TBL] [Abstract][Full Text] [Related]
19. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Krisinger MJ; Goebeler V; Lu Z; Meixner SC; Myles T; Pryzdial EL; Conway EM Blood; 2012 Aug; 120(8):1717-25. PubMed ID: 22802338 [TBL] [Abstract][Full Text] [Related]
20. Autoantibody-mediated arthritis in the absence of C3 and activating Fcγ receptors: C5 is activated by the coagulation cascade. Auger JL; Haasken S; Binstadt BA Arthritis Res Ther; 2012 Dec; 14(6):R269. PubMed ID: 23237573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]